Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05241340
Title Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)
Acronym RAD-VACCINE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Methodist Hospital Research Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.